gliclazide has been researched along with Disease Exacerbation in 5 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In responders, the initial dose (30 mg) of the gliclazide MR dosing regimen induced half of the maximum hypoglycaemic effect." | 2.71 | Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. ( Francillard, M; Frey, N; Holford, NH; Jochemsen, R; Laveille, C; Paraire, M, 2003) |
| "Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder." | 1.33 | A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. ( Danhof, M; de Winter, W; DeJongh, J; Eckland, D; Moules, I; Ploeger, B; Post, T; Urquhart, R, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alkhudhayri, S | 1 |
| Sajini, R | 1 |
| Alharbi, B | 1 |
| Qabbani, J | 1 |
| Al-Hindi, Y | 1 |
| Fairaq, A | 1 |
| Yousef, A | 1 |
| Mohammedi, K | 1 |
| Woodward, M | 1 |
| Zoungas, S | 1 |
| Li, Q | 1 |
| Harrap, S | 1 |
| Patel, A | 1 |
| Marre, M | 1 |
| Chalmers, J | 1 |
| Kassem, SA | 1 |
| Raz, I | 1 |
| Frey, N | 1 |
| Laveille, C | 1 |
| Paraire, M | 1 |
| Francillard, M | 1 |
| Holford, NH | 1 |
| Jochemsen, R | 1 |
| de Winter, W | 1 |
| DeJongh, J | 1 |
| Post, T | 1 |
| Ploeger, B | 1 |
| Urquhart, R | 1 |
| Moules, I | 1 |
| Eckland, D | 1 |
| Danhof, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
1 review available for gliclazide and Disease Exacerbation
| Article | Year |
|---|---|
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetic Angiopathies; Disease Progression; Enzyme In | 2009 |
2 trials available for gliclazide and Disease Exacerbation
| Article | Year |
|---|---|
Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diagnostic Techniques, Cardiovascular; Disea | 2016 |
Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Dose-Response Relationship, Drug; Fem | 2003 |
2 other studies available for gliclazide and Disease Exacerbation
| Article | Year |
|---|---|
Investigating the beneficial effect of aliskiren in attenuating neuropathic pain in diabetic Sprague-Dawley rats.
Topics: Amides; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Progression; Drug T | 2021 |
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Algorithms; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type | 2006 |